Neurocrine Biosciences Officially Begins Marketing Its New Parkinson's Disease Drug
Back in April, Neurocrine Biosciences (NASDAQ: NBIX) won Food and Drug Administration approval for its new drug Ogentys to be used in conjunction with Parkinson's disease treatment levodopa, but its launch was delayed by the COVID-19 pandemic. Now, the drug is finally hitting the market.
A COMT inhibitor, Ongentys reduces symptoms by interfering with an enzyme that breaks down the commonly prescribed Parkinson's drug levodopa. By extending levodopa's bioavailability, Ongentys reduces the periods when patients experience the involuntary movements (dyskinesia) that are among the disease's symptoms.
IMAGE SOURCE: GETTY IMAGES.
Source Fool.com
